The Trump administration’s recent health policy reforms have reignited debates over ivermectin usage, highlighting the tension between federal oversight and patient autonomy. As HHS consolidates medical decision-making powers, state-level conflicts, partisan disputes, and advocacy group interventions increasingly shape the national conversation about alternative therapies.
This article...
English
العربية
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Português
Tiếng Việt